Sturm, Ruger & Company, Inc. (NYSE:RGR) Releases Quarterly Earnings Results, Meets Expectations

Sturm, Ruger & Company, Inc. (NYSE:RGR) released its earnings results on Wednesday. The company reported $0.62 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.62, Zacks reports. The firm had revenue of $145.78 million during the quarter, compared to analyst estimates of $137.77 million. Sturm, Ruger & Company, Inc. had a return on equity of 9.47% and a net margin of 5.70%. During the same period last year, the business posted $0.58 earnings per share.

Sturm, Ruger & Company, Inc. Trading Down 1.6 %

NYSE:RGR traded down $0.63 during midday trading on Friday, hitting $39.18. 32,910 shares of the company were exchanged, compared to its average volume of 135,054. The company has a fifty day simple moving average of $35.53 and a 200 day simple moving average of $38.80. Sturm, Ruger & Company, Inc. has a fifty-two week low of $34.11 and a fifty-two week high of $48.20. The company has a market capitalization of $657.88 million, a PE ratio of 22.09 and a beta of 0.18.

Sturm, Ruger & Company, Inc. Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $0.96 dividend on an annualized basis and a yield of 2.45%. This is a boost from Sturm, Ruger & Company, Inc.’s previous quarterly dividend of $0.11. Sturm, Ruger & Company, Inc.’s dividend payout ratio (DPR) is presently 24.86%.

Sturm, Ruger & Company, Inc. Company Profile

Sturm, Ruger & Co, Inc engages in the business of designing, manufacturing, and selling firearms to domestic customers. It operates under the Firearms and Castings segments. The Firearms segment focuses on manufacturing and selling rifles, pistols, and revolvers principally to a number of federally licensed, independent wholesale distributors.